Wed, Dec 17, 2014, 7:13 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Threshold Pharmaceuticals Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • tredleon tredleon Dec 27, 2006 5:55 PM Flag

    4.10 x 4.15 at this moment

    The thing you have to remember is that the endpoint for the phase III trial is a very low bar - you are basically treating patients that are at the end of their rope and seeing if Glufo will extend their lives by a few months, which would be a success.

    I think this is part of the reason why the after-hours response to the phase II results is muted - the results don't seem all that impressive on the surface - no complete responders, only partial responders and stable disease. But again, you have to look at the treatment population - these people have advanced/metastatic cancer with a very poor prognosis (survival after conventional chemo treatment is on average less than a year), so adding a few months to that equation is significant.

    You have to recognize that Glufo is not expected to be a miracle drug that will cure these people - it is a supplementary therapy that attacks solid tumors from a different angle than conventional chemo, so the hope is it enhances response and survival, but is not a cure.

    That is why IMO the phase II trial is equally important as the phase III (Glufo alone on patients that have not responded to Gem alone) - it will show that Glufo enhances "first line" treatment, and so will hopefully be tested and used with new conventional chemo agents that come along down the road.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.96+0.05(+1.72%)Dec 17 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.